found that a homozygous SFTPA1 mutation drives type II lung and alveolar epithelial cell necrotic apoptosis in patients with IPF, and SFTPA1 is used as a biomarker of anti‐fibrosis drug treatment in patients with IPF. Here, SFTPA1 is linked to idiopathic pulmonary fibrosis.